Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder

  • Vertex Pharmaceuticals Incorporated VRTX and Entrada Therapeutics Inc TRDA announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle (EEV) therapeutics for myotonic dystrophy type 1 (DM1). 
  • The collaboration includes Entrada's program for DM1, ENTR-701, which is in late-stage preclinical development.
  • Under the terms of the agreement, Entrada will receive an upfront payment of $224 million and an equity investment of $26 million. 
  • Also see: Vertex Moves Its Alpha-1 Antitrypsin Deficiency Program Forward.
  • Entrada can receive up to $485 million as milestone payments and tiered royalties on future net sales.
  • The agreement includes a four-year global research collaboration whereby Entrada will continue to advance and receive payments for certain research activities related to ENTR-701 and additional DM1-related research activities. 
  • Vertex will be responsible for the global development, manufacturing, and commercialization of ENTR-701 and any additional programs stemming from Entrada's DM1 research efforts.
  • Price Action: TRDA shares are up 20.4% at $21.33 on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!